44 Results From the Phase 1/2 Study of Patritumab Deruxtecan (HER3-DXd), a HER3-Directed Antibody-Drug Conjugate (ADC), in Patients (pts) With HER3- Expressing Metastatic Breast Cancer (MBC)
ByIan E. Krop,Norikazu Masuda,Toru Mukohara,Shunji Takahashi,Takahiro Nakayama,Kenichi Inoue,Hiroji Iwata,Tatsuya Toyama,Yutaka Yamamoto,Damien Hansra,Masato Takahashi,Akihiko Osaki,Kumiko Koyama,Tatsuya Inoue,Takatoshi Yonekura,Joseph Mostillo,Shoichi Ohwada,Yoshimi Tanaka,David Sternberg,Kan Yonemori